INTRODUCTION
Migraine headaches can be debilitating if patients cannot control or minimize the symptoms, and they can substantially impair the quality of life. However, migraines can often be successfully controlled by the avoidance of triggers, lifestyle changes, and abortive treatment. In patients in whom these measures prove insufficient or unsatisfactory, prophylactic measures to prevent migraines may be needed.1 A common preventive measure is the use of prophylactic drugs, which will be the focus of this article. I will briefly mention nonpharmacologic or alternative measures.
SEARCH METHODS
The information given here is based on a MEDLINE search from 1966 to the present using the terms “migraine prevention” and “migraine prophylaxis.” The search was limited to English-language review articles and studies with human subjects. I also searched the Internet using the key word “migraine” to link to the Web sites of the Journal of the American Medical Association Migraine Information Center and the American Academy of Neurology.
Summary points
Not all patients are candidates for prophylactic therapy for migraine; physicians must evaluate whether prophylaxis is indicated in a patient
Prophylaxis of migraines is not a cure; abortive measures will still be necessary in most patients
A headache diary is essential to identify and avoid triggers and to evaluate therapy
For prophylactic drug therapy, choose the agent that has the potential for the highest benefit and lowest risk to the patient
Although their efficacy is questionable, alternative therapies may have some role in migraine prophylaxis
BEFORE STARTING PROPHYLAXIS
Patients for whom prophylactic therapy is indicated have the following migraine features:
More than 2 headaches per month, but fewer than 8 (>8 attacks per month usually indicate overuse of abortive therapy)2
Headaches less frequent but more prolonged (>2 days' duration) or severe attacks leading to substantial disability1,3
Migraines are refractory to abortive treatment measures
Therapies for acute attacks are intolerable, contraindicated, or overused (>2 per week)2,3,4
Migraines are predictable in occurrence
The patient has other migraine conditions such as migraine with prolonged aura or hemiplegic migraine5
Before prophylaxis is appropriate, the physician must evaluate whether proper and adequate abortive therapies have been instituted. Some patients overuse abortive measures, leading to rebound headaches. In these patients, the drug should be withdrawn before preventive therapy is initiated.2,6
A headache diary is essential for all patients who suffer from migraine headaches.7 If migraine triggers can be identified, prophylactic therapy may be unnecessary. If, however, the triggers are unavoidable or undetermined, drug therapy is indicated to try to prevent the migraines. If prophylactic therapy is initiated, a 2- to 3-month trial is generally needed to assess the efficacy of the regimen.5 Prophylaxis may be daily on a continuous basis or scheduled according to predetermined triggers, such as the onset of menses. The physician should evaluate previous prophylactic measures, if any, for adequacy and appropriateness. Women of childbearing age should be treated with caution because of the teratogenicity of most prophylactic drugs.2
Patients must also understand the goals, limits, and risks of migraine prophylaxis. The goals are to reduce the duration, frequency, and severity of the attacks to improve the patient's quality of life and minimize disability.5 Prophylactic therapy is rarely curative; therefore, abortive therapies continue to be necessary in most patients, although their effectiveness is usually increased when used with prophylactic drugs.6 A 50% reduction in the frequency of migraines is generally deemed successful.8 Compliance is a major issue because patients experience medication side effects before any benefit from prophylactic drugs.3
CHOOSING AN AGENT
Many drugs have proven efficacy in preventing migraine. Based on patient-specific indices, the agent with the highest risk-to-benefit ratio should be used. The efficacy, contraindications, precautions, side effects, concurrent disease states of the patient (“special indications”), compliance issues, and cost should all be considered.1,5,9 Side effects must be given special consideration because migraine sufferers have an increased frequency of adverse effects compared with other patients.2,3
Guidelines for migraine prophylaxis
Initiate the chosen drug at a low dose and titrate up (usually every 2-4 weeks) until benefits occur or side effects prevent any further increase in dose. Long-acting formulations may improve compliance2,5
A 2- to 3-month trial is needed to assess the efficacy of a regimen
After 1 year, try to withdraw the drug, even if it has been effective.
Use a drug that may benefit any comorbid conditions the patient has5
Prophylaxis should be monotherapy whenever possible. Combinations of drugs have not shown substantial benefit except in some patients with multiple comorbid conditions.2
Table 1.
β-Blockers in migraine prophylaxis |
---|
|
Approved by the Food and Drug Administration for migraine prevention
DRUGS WITH AN ESTABLISHED ROLE IN MIGRAINE PROPHYLAXIS
First-line agents
The first-line agents with the greatest efficacy are β-blockers, tricyclic antidepressants, and divalproex sodium or valproic acid. I have not considered agents unavailable in the United States, such as flunarizine, lisuride, and pizotifen.1 I have also excluded agents that have proved to be ineffective or for which proof of efficacy is limited.
β-Blockers
The scientific and clinical evidence supports β-blockers as the drugs of choice for the prevention of migraines.7 The most commonly used agent is propranolol hydrochloride. Generally, if 1 agent fails, another in its class may be tried, and this change may prove to be effective. It is imperative that abrupt stoppage of therapy is avoided.2 β-Blockers are not effective in reducing aura.7 In general, response to these agents is gradual, and it may take at least a month to see an effect.10 The use of β-blockers with intrinsic sympathomimetic activity (such as pindolol) should be avoided.11 The daily dose range for β-blockers in migraine prophylaxis, together with their side effects, precautions, and special indications, are given in the first box.5,6,7,10
Tricyclic antidepressants
Tricylic antidepressants are another class of medication considered as first-line treatment in migraine prophylaxis. Even without the presence of depression, these agents are effective in preventing migraines, and the response is usually more rapid (within 4 weeks) than with β-blockers.10,12,13 Combined use with β-blockers does not reduce the incidence of migraines, but it may reduce that of tension-type headaches.7 Although the entire class is considered useful in prophylaxis, tertiary amines, such as amitriptyline, are more effective than the secondary amines, such as nortriptyline.6 Amitriptyline hydrochloride is the first-line agent of choice among the tricyclic antidepressants.5 Physicians need to consider the differences in side-effect profiles of the various drugs when deciding which one to use (second box).5,6,7,10,14
Divalproex sodium or valproic acid
Divalproex and valproic acid are also first-line agents in migraine prevention, and the former has been approved by the Food and Drug Administration (FDA) for this indication (third box).5,6,7 The initial dose is usually from 250 mg daily, titrated up to 1,500 mg.5,7 If no benefit is seen at low doses, dose escalation is usually not helpful.15 A serum drug concentration of 50 to 120 mg/L is considered to be in the therapeutic range, but it is unclear whether such monitoring is necessary or, indeed, indicative of efficacy.10,16,17 Other anticonvulsants either have no efficacy or have not proved effective at this time.5
Second-line agents
Calcium channel blockers
Calcium channel blockers are effective second-line agents (fourth box).5,6,7,10 They are usually slower in onset than β-blockers, and an initial increase in headache frequency may occur on starting therapy. They are a viable alternative in patients who cannot tolerate β-blockers.6,
Table 2.
Tricyclic antidepressants in migraine prophylaxis |
---|
|
Table 3.
Divalproex sodium and valproic acid in migraine prophylaxis |
---|
|
Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used daily or intermittently. When migraine triggers are identified or are predictable—such as menstruation— intermittent therapy may be used (using NSAIDs 1 week before menses and then throughout menstruation).19,20,21 Naproxen sodium is the most commonly used NSAID for migraine prophylaxis (fifth box),5,6,7,10 and the dose is 1,100 mg daily. Other NSAIDs that may be substituted for naproxen are mefenamic acid, flurbiprofen sodium, fenoprofen calcium, ketoprofen, and aspirin.5 Adverse effects tend to be infrequent with short-term therapy but increase with extended treatment.3,5
Third-line agents
Two medications that have proved effective in prophylaxis but are reserved for severe or refractory cases are methysergide and phenelzine sulfate. Both should be reserved for use only by specialists in headache treatment.2,7
Methysergide is the fourth agent indicated and approved for migraine prophylaxis by the FDA. Because of its side-effects profile, numerous precautions, and contra-indications, it has become a last-line drug. Longer than 6 months of continuous use can lead to fatal retropleural, retroperitoneal, or cardiac fibrosis, and drug holidays must be instituted when methysergide is used.3,7,,
Table 4.
Calcium channel blockers in migraine prophylaxis |
---|
|
Table 5.
NSAIDs in migraine prophylaxis |
---|
|
Phenelzine—a monoamine oxidase inhibitor—has numerous precautions and contraindications. It should be considered only in severe refractory cases, specifically those that are compounded by tension headaches or atypical depression,7,22 and only in patients whose compliance can be expected. Phenelzine is difficult to use—it has several potentially dangerous interactions with other drugs, and it can cause hypertensive crises in patients who do not comply with a tyramine-free diet.6,7
DRUGS WITH AN UNCERTAIN OR UNPROVEN ROLE IN MIGRAINE PROPHYLAXIS
The efficacy of fluoxetine hydrochloride has not been well established in prophylaxis, but some experts already consider it a viable alternative to tricyclic antidepressants.5,6,7,14 Doses from 20 mg every other day to 40 mg a day have been used. Other selective serotonin-reuptake inhibitors may prove to be useful, but the evidence for their efficacy is so far weak or nonexistent.5
Some evidence exists that riboflavin (vitamin B2) in high doses (400 mg daily) has some effect in migraine prophylaxis. Because of its low cost and low side-effect profile, it may prove to be a useful alternative.23 Similarly, magnesium at doses of 400 to 600 mg daily may also be of benefit, but there is less evidence for its efficacy than that for riboflavin.5,24,25
NONPHARMACOLOGIC MEASURES IN PREVENTING MIGRAINE
The standard nonpharmacologic approach is the avoidance of triggers to migraines. Avoidance may lower head-ache frequency by 50%.26 The following are common migraine triggers:
POSSIBLE ALTERNATIVE THERAPIES FOR MIGRAINE PREVENTION
Feverfew, an herbal medication (Chrysanthemum parthenium), is marketed as being useful in migraine prevention, at a daily dose of 125 mg. Most data support the notion that feverfew is superior to placebo. However, a systematic review failed to substantiate its efficacy.30 Adverse effects are mild—usually gastrointestinal upset—but withdrawal may lead to increased frequency of headache, anxiety, and sleep disturbances. Its use should be avoided in pregnancy.31
Other alternative therapies are used by patients in migraine prevention:
Relaxation therapy—breathing exercises and muscle relaxation
Cognitive-behavioral therapy—identification and avoidance of behaviors or responses to migraines that may exacerbate a migraine attack
Biofeedback techniques—these rely on the premise that patients may be able to control physiologic responses of the body, such as to migraine attacks6
Homeopathy (no better than placebo in most studies)32
Acupuncture
Reflexology
Massage
Temperature changes (hot or cold packs)29
There is little evidence of the effectiveness of these therapies. However, because most do not cause any apparent harm, some patients may benefit from these options in treatment when used alone or as an adjunct to prophylactic medications.6
Acknowledgments
Special thanks to Kevin Landa, PharmD, for his assistance with this article.
Competing interests: None declared
Author: Dr Parsekyan received his Doctor of Pharmacy degree from the University of Southern California, Los Angeles, and is a pharmacist in Los Angeles.
References
- 1.Becker WJ. Evidence based migraine prophylactic drug therapy. Can J Neurol Sci 1999;26(suppl 3): S27-S32. [DOI] [PubMed] [Google Scholar]
- 2.Tfelt-Hansen P. Prophylactic pharmacotherapy of migraine: some practical guidelines. Neurol Clin 1997;15: 153-165. [DOI] [PubMed] [Google Scholar]
- 3.Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998;56: 811-824. [DOI] [PubMed] [Google Scholar]
- 4.Young WB, Silberstein SD, Dayno JM. Migraine treatment. Semin Neurol 1997;17: 325-333. [DOI] [PubMed] [Google Scholar]
- 5.Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM, for the US Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [Am Acad Neurol Web site]. April 25, 2000. Available at: http://www.aan.com/public/practiceguidelines/05.pdf. Accessed August 15, 2000.
- 6.Evans RM. Managing migraine today (II): pharmacologic and nonpharmacologic treatment [JAMA Migraine Information Center Web site]. October 1998. Available at: http://www.ama-assn.org/special/migraine/treatmnt/managmig/managmig.htm. Accessed August 6, 2000.
- 7.Noble SL, Moore KL. Drug treatment of migraine: part II. preventive therapy. Am Fam Physician 1997;56: 2279-2286. [PubMed] [Google Scholar]
- 8.Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice: Canadian Headache Society. CMAJ 1997;156: 1273-1287 [published erratum appears in CMAJ 1997;157:1354]. [PMC free article] [PubMed] [Google Scholar]
- 9.Tfelt-Hansen P. Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Cephalalgia 1995;15(suppl 15): 29-32. [DOI] [PubMed] [Google Scholar]
- 10.Maizels M. The clinician's approach to the management of headache. West J Med 1998;168: 203-212. [PMC free article] [PubMed] [Google Scholar]
- 11.Tfelt-hansen P, Welch KMA. General principles of pharmacological treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993: 403-407.
- 12.Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976;26: 121-127. [DOI] [PubMed] [Google Scholar]
- 13.Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36: 695-699. [DOI] [PubMed] [Google Scholar]
- 14.Schwetschenau KH. Prophylactic treatment of migraine: possibilities for pharmacist interventions. Pharmacy Times 2000. Apr; pp 72-78.
- 15.Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia 1997;17: 81-83. [DOI] [PubMed] [Google Scholar]
- 16.Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44: 647-651. [DOI] [PubMed] [Google Scholar]
- 17.Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52: 281-286. [DOI] [PubMed] [Google Scholar]
- 18.Campbell JK, Zagami A. Hemiplegic migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993: 409-411.
- 19.Raskin NH. Migraine: treatment. In: Headache. 2nd ed. New York: Churchill Livingstone; 1988.
- 20.Davidoff RA. Special situations. In: Migraine: Manifestations, Pathogenesis, and Management. Philadelphia: Davis; 1995: 248-266.
- 21.MacGregor EA. Menstruation, sex hormones, and migraine. Neurol Clin 1997;15: 125-141. [DOI] [PubMed] [Google Scholar]
- 22.Davidoff RA. Migraine: Manifestations, Pathogenesis, and Management. Philadelphia: Davis; 1995.
- 23.Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998;50: 466-470. [DOI] [PubMed] [Google Scholar]
- 24.Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16: 257-263. [DOI] [PubMed] [Google Scholar]
- 25.Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine—a double-blind placebo-controlled study. Cephalalgia 1996;16: 436-440. [DOI] [PubMed] [Google Scholar]
- 26.Blau JN, Thavapalan M. Preventing migraine: a study of precipitating factors. Headache 1998;28: 481-483. [DOI] [PubMed] [Google Scholar]
- 27.Horne M. Treating headaches: a conceptual framework. Aust Fam Physician 1998;27: 579-586. [PubMed] [Google Scholar]
- 28.Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the nonpharmacologic management of migraine in clinical practice: Canadian Headache Society. CMAJ 1998;159: 47-54. [PMC free article] [PubMed] [Google Scholar]
- 29.Knott L. Taking control of migraine and headache. Practitioner 1999;243: 33-38. [PubMed] [Google Scholar]
- 30.Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998;18: 704-708. [DOI] [PubMed] [Google Scholar]
- 31.Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999;56: 125-138. [DOI] [PubMed] [Google Scholar]
- 32.Ernst E. Homeopathic prophylaxis of headaches and migraine? a systematic review. J Pain Symptom Manage 1999;18: 353-357. [DOI] [PubMed] [Google Scholar]